Impact Factor

Issue 57
Biorepositories for cancer research in developing countries
Issue 56
Secobarbital in Seattle: why lose sleep?
Issue 55
Post traumatic stress disorder - prevalent and persistent
Issue 54
Investment biobanking increased returns from tissue samples
Issue 53
Aprepitant and control of emesis induced by five-day chemotherapy
Issue 52
Diabetes risk after radiation - not out of the woods

Issue 51
Gastro-oesophageal cancer - is CROSSing over so hard to do?
Cetuximab dosing by rash - is the scaling of EVEREST meaningful?
Issue 50
For localised prostate cancer, does technology equal pregress?
Gemtuzumab ozogamicin in acute myeloid leukaemia
Issue 49
Salvage chemotherapy in gastric cancer - more than a straw?
Manufacturer sponsorship bias in economic analyses matters
Issue 48
Localised non-bulky Hodgkin lymphoma - future questions
First-line bevacizumab for ovarian cancer
Issue 47
The importance of local control in pancreatic cancer
Time for another rethink on prostate cancer screening
Issue 46
The silent minority - unpublished data on cancer care
Hodgkin lymphoma - absence of evidence not evidence of absence
Issue 45
An important piece of the localised prostate cancer puzzle
Front-line therapy in lung cancer with mutations in EGFR
Issue 44
Denosumab-- a new option for solid tumours metastatic to bone
Perioperative therapy improves gastro-oesophageal cancer survival

Issue 43
Rituximab for follicular lymphoma: maintaining an opend mind
Aster-- another flower in the diagnostic field of lung cancer?

Issue 42
Hypoxia modification with radiotherapy for bladder cancer
An 18-gene signature (ColoPrint) for colon cancer prognosis

Issue 41
Failure of bevacizumab in early-stage colon cancer
Ultra-targeted accelerated partial breast irradiation using TARGIT--a cautionary note

Issue 40
Gemcitabine alone or plus cisplatin for biliary tract cancer?
Molecular selection for 'smart' study design in lung cancer

Issue 39
200 mg/m2 melphalan--the gold standard for multiple myeloma
Optimising chemotherapy and radiotherapy for anaplastic glioma

Issue 38
Neoadjuvant trial design:  time for a brave new world?
Are macrophages the bad guys in Hodgkin lymphoma?

Issue 37
Chemoradiation in head-an-neck cancer--are we any closer?
Preoperative biliary drainage--better stents in specialised centres are needed

Issue 36
Trials and tribulations in primary CNS lymphoma
Androgen deprivation therapy for prostate cancer: true love or heartbreak?

Issue 35

Future directions in multimodality therapy for NSCLC
Sunitinib versus interferon-a in metastatic RCC
Issue 34
Adjuvant chemotherapy in older patients with breast cancer
PET-CT imaging in non-small-cell lung cancer
Issue 33
GIST adjuvant therapy - some answers and more questions
The role of lymphadenectomy in the staging of endometrial cancer
Issue 32
Effect of treatment interrunptions in prostate cancer
Endocrine-therapy-related symptoms and breast cancer
Issue 31
Bortezomib in newly diagnosed multiple myeloma
Vaccine trials in melanoma - time for reflection
Issue 30
Certuximab therapy for patients with advanced squamous cell carcinomas of the head and neck
Optimal timing of surgery after preoperative chemoradiotherapy for rectal cancer
Issue 29
Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma?
How does extended lymphadenectomy influence practical care for patients with gastric cancer?
Issue 28
Adoptive transfer of antigen-specific CH4+T cells in the treatment of metastic melanoma
Determining the survival benefit of adjuvant radiotherapy in patients with node-positive head and neck cancer
Issue 27
Concomitant difluoromethylornithine/sulindac chemoprevention of colorectal adenomas: a major clinical advance
The ROC 'n' role of the multiplex assay for early detection of ovarian cancer
Issue 26
Adjuvant EBRT improves survival in patients with lymph-node-negative pancreatic cancer
Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma
Issue 25
Does prophylactic cranial irradation reduce the incidence of brain metastases in extensive small-cell lung cancer?
Comparison of gemcitabine plus platinum analogue with gemcitabine alone in advanced pancreatic cancer
Issue 24
Outcomes after cisplatin alone or in combination regimens versus hydoxyurea during pelvic irradiation for cervical cancer
Are metastatic testicular tumours curable with high-dose chemotherapy and stem-cell rescue?
Issue 23
Are patients with multiple hepatic metastases from colorectal cancer candidates for surgery?
Is drug treatment superior to allografting as first-line therapy in chronic myeloid leukaemia?
Issue 22
Does a prompt list help patients and caregivers to ask questions about cancer prognosis and care?
Does adjuvant radiotherapy increase survival in patients with Merkel cell carcinoma of the skin?
Issue 21
Is surgery really necessary following chemoradiation for patients with locally advanced cancer of the oesophagus?
Is rituximab maintenance therapy useful following rituximab salvage in refractory or relapsed follicular lymphoma?
Issue 20
Could a pelvic abdominal symptom index assist in early detection of ovarian cancer?
Is stereotactic radiosurgery the best treatment option for patients with spinal metastases?
Issue 19
Cardiac side-effects of trastuzumab: lessons learned from targeting cancer pathways
Magnetic resonance imaging for rectal cancer
Issue 18
What radiation dose is safe in patients with non-small-cell lung cancer?
Should patients with anaplastic oligodendroglial tumours receive adjuvant chemotherapy?
Issue 17
Does a new model improve decisions about mismatch-repair genetic testing and Lynch syndrome identification?
Is breast conservation a reasonable option for women with BRCA-associated breast cancer?
Issue 16
Gene expression profiling for individualised breast cancer chemotherapy: success of not?
Poor correlation between physician and patient assessment of quality of life in palliative care
Issue 15
Does chemotherapy given directly to the liver improve survival in patients with hepatic metastasis?
Should patients with ovarian cancer receive interperitoneal chemotherapy following initial cytoreductive surgery?
Issue 14
Does trastuzumab increase the risk of isolated CNS metastases in patients with breast cancer?
Radiation dose for prostate cancer: is more better?
Issue 13
Does regular use of aspirin reduce the risk of colorectal cancer?
Factors predictive for response of folliculare and mantle cell lymphoma to rituximab
Issue 12
When should radiotherapy for low-grade glioma be given: straight after surgery or at progression?
Is intraoperative lymphatic mapping and sentinel node biopsy effective and safe in early-stage melanoma?
Issue 11
Is radical prostatectomy of benefit in men with localised prostate cancer?
Issue 10
Radiofrequency ablation in hepatocellular carcinoma
Relapsed Hodgkin's lymphoma: new twist to the standard regimen
Issue 9
Lung cancer: spotting the symptoms
Issue 8
Minimising radiotherapy in children with rhabdomyosarcoma
Could COX -2s stage a comeback in cancer?
Issue 7
Sentinel node biopsy gets an excellent report
Glioblastoma: two studies herald a new start
Follicular lymphoma: a side-lined drug excites new interest
Issue 6
Neoadjuvant studies offer mixed messages
Issue 5
Has tamoxifen had its day?
Issue 4
Doctors who shun guidelines get worse results
Issue 3
Treatment of metastatic CRC takes two steps forward
Issue 2
Tailor-made vaccine hailed as milestone in renal-cell cancer
Issue 1
Advanced head and neck cancers